Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
89Zr-brentuximab
- Development stage
- Unknown
- Lead developer
- University Medical Center Groningen
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
89Zr-brentuximab (specifically 89Zr-brentuximab vedotin) is an immuno-positron emission tomography (immuno-PET) imaging agent developed primarily by researchers at the Universitair Medisch Centrum Groningen (UMCG). It consists of the CD30-targeting antibody-drug conjugate (ADC) brentuximab vedotin labeled with the positron-emitting radioisotope zirconium-89 (89Zr), typically via a desferrioxamine (DFO) chelator. This radiopharmaceutical is designed to non-invasively visualize and quantify CD30 expression and antibody biodistribution in patients with lymphomas, such as Hodgkin lymphoma and diffuse large B-cell lymphoma (DLBCL). By tracking the uptake of the antibody in tumor lesions, 89Zr-brentuximab serves as a companion diagnostic to identify patients most likely to benefit from therapeutic treatment with brentuximab vedotin (Adcetris).
- Other names
- 89Zr-labeled brentuximab vedotinZirconium-89 brentuximab vedotinZirconium89 brentuximab vedotinZirconium 89 brentuximab vedotin
02
Targets
TUBB (Tubulin (alpha and beta subunits))CD30 (CD30 antigen)
Beyond the preview
Go deeper on 89Zr-brentuximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 89Zr-brentuximab.